CA3062424A1 - Anti-il-1r3 antibodies for use in inflammatory conditions - Google Patents

Anti-il-1r3 antibodies for use in inflammatory conditions Download PDF

Info

Publication number
CA3062424A1
CA3062424A1 CA3062424A CA3062424A CA3062424A1 CA 3062424 A1 CA3062424 A1 CA 3062424A1 CA 3062424 A CA3062424 A CA 3062424A CA 3062424 A CA3062424 A CA 3062424A CA 3062424 A1 CA3062424 A1 CA 3062424A1
Authority
CA
Canada
Prior art keywords
antibody
seq
cdr
il1r3
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3062424A
Other languages
English (en)
French (fr)
Inventor
Stephan Fischer
Karsten Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Original Assignee
MAB Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAB Discovery GmbH filed Critical MAB Discovery GmbH
Publication of CA3062424A1 publication Critical patent/CA3062424A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3062424A 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions Pending CA3062424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17169953.1 2017-05-08
EP17169953.1A EP3401332A1 (en) 2017-05-08 2017-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions
PCT/EP2018/061846 WO2018206565A1 (en) 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions

Publications (1)

Publication Number Publication Date
CA3062424A1 true CA3062424A1 (en) 2018-11-15

Family

ID=58698976

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062424A Pending CA3062424A1 (en) 2017-05-08 2018-05-08 Anti-il-1r3 antibodies for use in inflammatory conditions

Country Status (7)

Country Link
US (2) US11639392B2 (enExample)
EP (2) EP3401332A1 (enExample)
JP (3) JP7315472B2 (enExample)
CN (1) CN110831670A (enExample)
AU (2) AU2018267092B2 (enExample)
CA (1) CA3062424A1 (enExample)
WO (1) WO2018206565A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
ES3042097T3 (en) 2017-03-09 2025-11-18 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
CN111225924B (zh) 2017-09-19 2023-10-10 Mab发现股份有限公司 激动性cd40抗体
TW202021618A (zh) * 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
AU2019405782A1 (en) * 2018-12-21 2021-06-17 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
US20220298234A1 (en) * 2019-05-13 2022-09-22 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
US20220411517A1 (en) 2021-05-21 2022-12-29 Leo Pharma A/S IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof
WO2024062074A1 (en) * 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
CA2056102C (en) 1990-11-26 2003-03-25 Petrus Gerardus Antonius Steenbakkers Method for the production of antibodies
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7049095B2 (en) 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
US20030049255A1 (en) 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
AU2003248370A1 (en) 2002-02-27 2003-09-09 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
PL222220B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2831379T3 (es) 2003-10-09 2021-06-08 Ambrx Inc Derivados poliméricos para la modificación selectiva de proteínas
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
WO2005073164A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CA2655511C (en) 2005-07-01 2017-03-21 John Schrader Methods of isolating cells and generating monoclonal antibodies
KR101460932B1 (ko) 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
NZ572807A (en) 2006-05-19 2011-10-28 Alder Biopharmaceuticals Inc Culture method for obtaining a clonal population of antigen-specific b cells
CN102046660A (zh) 2008-03-26 2011-05-04 塞勒兰特治疗公司 骨髓性血液学增殖性病症相关的免疫球蛋白和/或toll样受体蛋白及其用途
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
DK2400298T3 (da) 2010-05-28 2013-09-02 Hoffmann La Roche Enkelt B-celle-dyrkningsfremgangsmåde og specifik antistoffremstilling
ES2714716T3 (es) 2011-01-19 2019-05-29 Cantargia Ab Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EP2935334A4 (en) 2012-12-21 2016-10-26 Cellerant Therapeutics Inc ANTIBODIES THAT FIX TO MEMBRANE-RELATED IL1 RAPID
US10126304B2 (en) 2013-01-16 2018-11-13 George Mason Research Foundation, Inc. Binding domain mapping
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) * 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions

Also Published As

Publication number Publication date
AU2024202910A1 (en) 2024-05-23
WO2018206565A9 (en) 2019-12-26
WO2018206565A1 (en) 2018-11-15
US20230383000A1 (en) 2023-11-30
AU2018267092B2 (en) 2024-02-08
EP3401332A1 (en) 2018-11-14
AU2018267092A1 (en) 2019-11-14
JP7315472B2 (ja) 2023-07-26
CN110831670A (zh) 2020-02-21
JP7605916B2 (ja) 2024-12-24
US11639392B2 (en) 2023-05-02
JP2025038044A (ja) 2025-03-18
EP3621693A1 (en) 2020-03-18
JP2020519590A (ja) 2020-07-02
JP2023134618A (ja) 2023-09-27
US20200140559A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
US20230383000A1 (en) Anti-il-1r3 antibodies for use in inflammatory conditions
US12024564B2 (en) Humanized anti-IL-1R3 antibodies
HK40116833A (en) Humanized anti-il-1r3 antibodies
HK40003550B (en) Humanized anti-il-1r3 antibodies
HK40003550A (zh) 人源化抗il-1r3 抗体
EA040391B1 (ru) Гуманизированные анти-il-1r3 антитела
EA049751B1 (ru) Гуманизированные анти-il-1r3 антитела

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230501

EEER Examination request

Effective date: 20230501

EEER Examination request

Effective date: 20230501